In our analysis of 75 NSCLC cases, 28% of the tumor samples overexpress HER2 and there seems to be a trend that HER2 overexpression is more common in adenocarcinoma than in other histotypes (p=0.074), which awaits further confirmation in larger samples. This evidence concerns the gene ERBB2 and adenocarcinoma.